Vaxfab Enterprises Auditors Issue Disclaimer of Opinion, Flag Going Concern Risk

Standalone Revenue: Q4 March 2026: ₹8.83 crore
Consolidated Revenue: Q4 March 2026: ₹45.99 crore

Reader Takeaway: Unverified financials due to audit disclaimer; significant doubt over company's ability to continue operations.

What just happened

Vaxfab Enterprises Ltd. has received a Disclaimer of Opinion from its statutory auditors, M/S Chandabhoy & Jassoobhoy, on its standalone and consolidated financial results for the quarter and year ended March 31, 2026. This is the most severe audit qualification, meaning the auditors could not obtain sufficient evidence to form an opinion.

Why this matters

The audit disclaimer renders the company's reported financial figures unreliable. More critically, auditors have highlighted a material uncertainty regarding the 'going concern' assumption, raising doubts about Vaxfab's ability to continue operating in the future. This puts investor capital at significant risk.

The backstory

Auditors cited previous management's failure to maintain adequate records, including accounting books, sales, purchases, inventory, and trade receivables/payables. They also noted missing balance confirmations, unsecured loans without proper agreements, and non-compliance with the MSMED Act, 2006.

What changes now

Financial statements presented by Vaxfab are not independently verified by auditors. The 'going concern' uncertainty implies potential operational disruptions and financial instability. Investors must treat all reported financial metrics with extreme caution.

Risks to watch

The primary risks include the lack of verified financial data, the possibility of the company ceasing operations, and potential issues arising from poorly documented loans and regulatory non-compliance.

Peer comparison

Companies with audit disclaimers and going concern warnings typically see significant drops in market value and investor confidence compared to peers with clean audit reports. Vaxfab's situation is a critical red flag.

Context metrics (time-bound)

• Standalone Revenue: ₹8.83 crore for Q4 March 2026.
• Standalone Profit: ₹3.02 crore for Q4 March 2026.
• Consolidated Revenue: ₹45.99 crore for Q4 March 2026.
• Consolidated Profit: ₹2.14 crore for Q4 March 2026.
• (Note: These figures are subject to the audit disclaimer.)

What to track next

Investors should closely monitor any further disclosures from Vaxfab regarding efforts to rectify its record-keeping issues and address the auditors' concerns. Any news on the company's operational status or restructuring plans will be crucial.